BROOKLYN IMMUNOTHERAPEUTICS - COM (BTX)

CUSIP: 114082100

Q2 2021 13F Holders as of 30 Jun 2021

Type / Class
Equity / COM
Total 13F shares
4,241,481
Share change
+4,134,935
Total reported value
$76,391,577
Put/Call ratio
237%
Price per share
$18.01
Number of holders
40
Value change
+$75,365,412
Number of buys
36
Number of sells
7

Quarterly Holders Quick Answers

What is CUSIP 114082100?
CUSIP 114082100 identifies BTX - BROOKLYN IMMUNOTHERAPEUTICS - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of BROOKLYN IMMUNOTHERAPEUTICS - COM (BTX) as of Q2 2021

As of 30 Jun 2021, BROOKLYN IMMUNOTHERAPEUTICS - COM (BTX) was held by 40 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 4,241,481 shares. The largest 10 holders included BlackRock Inc., Cypress Point Wealth Management, LLC, STATE STREET CORP, VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, Nuveen Asset Management, LLC, NORTHERN TRUST CORP, SUSQUEHANNA INTERNATIONAL GROUP, LLP, Bank of New York Mellon Corp, and CHARLES SCHWAB INVESTMENT MANAGEMENT INC. This page lists 40 institutional shareholders reporting positions in this security for the Q2 2021 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.